Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: Proceed with caution

Annals of Hematology

Volumn 86, Issue 8, 2007, Pages 599-607

  Choquet, Sylvain ^a   Oertel, Stephan ^b   LeBlond, Veronique ^a   Riess, Hanno ^c   Varoqueaux, Nathalie ^b   Dörken, Bernd ^c   Trappe, Ralf ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chemotherapy; IPI; Prognosis; Prognostic factors; PTLD; Risk adapted therapy; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER RADIOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34347395765     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0298-2     Document Type: Article

References (33)

1. Penn I, Hammond W, Brettschneider L, Starzl TE (1969) Malignant lymphomas in transplantation patients. Transplant Proc 1:106-112
2. Dodd GD III, Greenler DP, Confer SR (1992) Thoracic and abdominal manifestations of lymphoma occurring in the immunocompromised patient. Radiol Clin North Am 30(3):597-610
3. Pickhardt PJ, Siegel MJ (1999) Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology 213(1):73-78
4. Dotti G, Fiocchi R, Motta T et al (2002) Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome. Transplantation 74(8):1095-1102
5. Bakker NA, van Imhoff GW, Verschuuren EA et al (2005) Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 19(3):327-334
6. Harris NL, Ferry JA, Swerdlow SH (1997) Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Sem Diagn Pathol 14(1):8-14
7. Leblond V, Dhedin N, Mamzer Bruneel MF et al (2001) Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 19(3):772-778
8. Tsai DE, Hardy CL, Tomaszewski JE et al (2001) Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71(8):1076-1088
9. Starzl TE, Nalesnik MA, Porter KA et al (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1(8377):583-587
10. Oertel SH, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB (2002) Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 118(4):1120-1123
11. Mentzer SJ, Perrine SP, Faller DV (2001) Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis 3(3):177-185
12. Mamzer-Bruneel MF, Lome C, Morelon E et al (2000) Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 18(21):3622-3632
13. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86(9):3333-3340
14. Choquet S, Trappe R, Leblond V, Jaeger U, Davi F, Oertel S (2007) CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Efficacy, toxicity and factors predicting survival: A retrospective study of 26 cases with a long term follow up of 8.8 years. Haematologica 92:273-274
15. Svoboda J, Kotloff R, Tsai DE (2006) Management of patients with post-transplant lymphoproliferative disorder: The role of rituximab. Transpl Int 19(4):259-269
16. Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23(18):4117-4126
17. Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379-391
18. Garrett TJ, Chadburn A, Barr ML et al (1993) Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 72(9):2782-2785
19. Norin S, Kimby E, Ericzon BG et al (2004) Posttransplant lymphoma-a single-center experience of 500 liver transplantations. Med Oncol 21(3):273-284
20. Elstrom RL, Andreadis C, Aqui NA et al (2006) Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 6(3):569-576
21. Buell JF, Gross TG, Hanaway MJ et al (2005) Chemotherapy for posttransplant lymphoproliferative disorder: The Israel Penn International Transplant Tumor Registry experience. Transplant Proc 37(2):956-957
22. Jain AB, Marcos A, Pokharna R et al (2005) Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: Long-term experience from a single center. Transplantation 80(12):1692-1698
23. Oertel SH, Verschuuren E, Reinke P et al (2005) Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5(12):2901-2906
24. Choquet S, Leblond V, Herbrecht R et al (2006) Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 107:3053-3057
25. Ghobrial IM, Habermann TM, Ristow KM et al (2005) Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 46(2):191-196
26. Choquet S, Levy V, Leblond V (2004) Identification of prognostic factors in post-transplantation lymphoproliferative disorders. Bull Cancer 91(4):373-378
27. Czuczman MS, Grillo-Lopez AJ, Alkuzweny B, Weaver R, Larocca A, McLaughlin P (2006) Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma 47(9):1830-1840
28. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5):1504-1508
29. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235-242
30. Trappe R, Oertel SH, Choquet S, LeBlond V, Papp-Vary M, Riess H (2005) Sequential treatment with the anti-CD 20 antibody rituximab and CHOP+ GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): First results of a multicenter phase II study. Blood (ASH Annual Meeting Abstracts) 106(11):932
31. Plosker GL, Figgitt DP (2003) Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63(8):803-843
32. Oertel S, Trappe RU, Zeidler K et al (2006) Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 85(7):478-484
33. Bakker NA, Verschuuren EA, Erasmus ME et al (2007) Epstein-Barr virus-DNA load monitoring late after lung transplantation: A surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 83(4):433-438